Long-term Effects of Ublituximab in Relapsing Multiple Sclerosis: A Comparative Study

In a study analyzing long-term outcomes in relapsing multiple sclerosis, ublituximab showed a decline in annualized relapse rate (ARR) and reduced hazards for disability progression compared to ocrelizumab and ofatumumab, with improvements noted over five years.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42832972)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Why it matters

This is significant as it suggests potential benefits of ublituximab in managing long-term effects of relapsing multiple sclerosis, but results are based on indirect comparisons and further investigation is needed.

What this does not prove

The findings are from an unanchored matching-adjusted indirect comparison, which limits direct comparisons and should be viewed with caution due to inherent methodological limitations.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Other
Participants / samples: Not reported
Randomised: No
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: RRMS
Publication date: 2026-09-30
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Primary evidenceLong-term comparative outcomes in relapse activity and disability progression among anti-CD20 therapies in relapsing multiple sclerosis: An unanchored matching-adjusted indirect comparison. ↗DOI: 10.1016/j.msard.2026.107953

Supporting passages (11)

study phaseMETHODS: An unanchored matching-adjusted indirect comparison (MAIC) was conducted to explore five-year comparative outcomes in annualized relapse rate (ARR) and 24-week confirmed disability progression (CDP24) between ublituximab, ocrelizumab and ofatumumab.

study designMETHODS: An unanchored matching-adjusted indirect comparison (MAIC) was conducted to explore five-year comparative outcomes in annualized relapse rate (ARR) and 24-week confirmed disability progression (CDP24) between ublituximab, ocrelizumab and ofatumumab.

subjectsIndividual patient data from the ULTIMATE I/II trials were reweighted to match published baseline characteristics from the OPERA I/II and ASCLEPIOS I/II trials.

randomizedBACKGROUND: Anti-CD20 monoclonal antibodies are widely used in relapsing multiple sclerosis (RMS), but the absence of head-to-head randomized trials limits direct long-term comparisons between agents.

peer reviewedThese findings should be interpreted carefully within the assumptions and inherent limitations of the unanchored MAIC approach.

relevant ms typesBACKGROUND: Anti-CD20 monoclonal antibodies are widely used in relapsing multiple sclerosis (RMS), but the absence of head-to-head randomized trials limits direct long-term comparisons between agents.

comparatorUblituximab reduced the CDP24 hazard versus ocrelizumab (hazard ratio [HR] 0.560; 95% CI: 0.380-0.826) and ofatumumab (HR 0.509; 95% CI: 0.350-0.741), with 240-week RMST gains of 8 and 13 weeks, respectively.

primary endpointMETHODS: An unanchored matching-adjusted indirect comparison (MAIC) was conducted to explore five-year comparative outcomes in annualized relapse rate (ARR) and 24-week confirmed disability progression (CDP24) between ublituximab, ocrelizumab and ofatumumab.

findingsCONCLUSIONS: These findings suggest directionally favorable long-term outcomes with ublituximab compared with the other two comparators.

limitationsThese findings should be interpreted carefully within the assumptions and inherent limitations of the unanchored MAIC approach.

publication datePublication date: 2026-09-30

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.